Loading
Life sciences · Journal article
Expert Opinion on Therapeutic Targets · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Certain immune signaling pathways contribute to cancer progression by promoting tumor immune evasion through immune checkpoint activation, immunosuppressive cytokine production, metabolic depletion, and altered intracellular signaling. Small interfering RNAs (siRNAs) provide a programmable strategy for selectively silencing genes involved in immunosuppression, offering a targeted approach to enhance antitumor immunityAreas covered This review highlights the rationale for targeting immune regulatory factors with siRNA in cancer immunotherapy. Key targets include immune checkpoints (e.g. programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4), immunosuppressive mediators (e.g. transforming growth factor beta 1 and indoleamine 2,3-dioxygenase 1), and intracellular regulators (e.g. suppressor of cytokine signaling 1 and signal transducer and activator of transcription 3). Preclinical and early clinical studies show that silencing these targets restores T-cell activity, improves antigen presentation, remodels the tumor microenvironment, and enhances anti-tumor immunity. Additionally, advances in siRNA delivery methods are accelerating clinical translation.Expert opinion By silencing genes involved in immune suppression, siRNAs can restore T cell activation and improve the efficacy of cancer vaccines and adoptive cell therapies. However, significant challenges remain, including achieving efficient cell-specific delivery and minimizing off-target effects.